A new shared services system built around an advanced processing chip was released jointly at the RSNA meeting by TeraRecon and Fukuda-Denshi.
A new shared services system built around an advanced processing chip was released jointly at the RSNA meeting by TeraRecon and Fukuda-Denshi.
The UF-850XTD, a digital ultrasound system capable of cardiac and general imaging, offers continuous wave Doppler with high-frame-rate color flow imaging and a phased-array sector probe. The system uses high-frequency, convex, linear, and phased-array transducers and can be expanded to incorporate 3D imaging.
The midrange scanner is based on TeraRecon's XTrillion digital multibeam chip technology, which increases frame rates and axial resolution. The digital beam-forming technology also decreases noise to improve the sensitivity of images and the efficiency of ultrasound operators, particularly during the performance of Doppler studies. XTrillion digital signal processing coupled with tissue harmonics eliminates phase lapses that interfere with image sharpness.
The UF-850XTD comes with a 15-inch LCD or CRT monitor. Key configuration and placement have been designed to improve efficiency of operation and reduce musculoskeletal stress for the operator.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.